{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:10:47Z","timestamp":1780416647079,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.107022","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T15:47:09Z","timestamp":1768751229000},"page":"107022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Baseline severe disability as a predictor of treatment escalation to rituximab in AQP4-IgG\u2013positive NMOSD patients: A retrospective cohort study"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4583-6989","authenticated-orcid":false,"given":"Chayangkoon","family":"Siripornmongkol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metha","family":"Apiwattanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saharat","family":"Aungsumart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2026.107022_bib0001","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1038\/s41598-023-33827-3","article-title":"White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"13","author":"Akaishi","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2026.107022_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577236","article-title":"Risk factors of attacks in neuromyelitis optica spectrum disorders","volume":"343","author":"Akaishi","year":"2020","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.msard.2026.107022_bib0003","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/s00415-020-10377-6","article-title":"Impact of comorbid Sj\u00f6gren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders","volume":"268","author":"Akaishi","year":"2021","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107022_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229028","article-title":"Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: economic evaluation and budget impact analysis","volume":"15","author":"Aungsumart","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2026.107022_bib0005","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fneur.2023.1099376","article-title":"A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder","volume":"14","author":"Berthele","year":"2023","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107022_bib0006","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458513515085","article-title":"Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset","volume":"20","author":"Collongues","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107022_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.866824","article-title":"Serum and cerebrospinal fluid biomarkers in Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disease","volume":"13","author":"Dinoto","year":"2022","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107022_bib0008","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.26858","article-title":"Time to disability milestones and annualized relapse rates in NMOSD and MOGAD","volume":"95","author":"Duchow","year":"2024","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107022_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70243","article-title":"Rituximab as first-line compared to escalation immunotherapy is associated with lower disability accumulation in aquaporin-4-IgG-positive Neuromyelitis optica spectrum disorder: a multicenter cohort study from Germany and the United Kingdom","volume":"32","author":"Engels","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107022_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1865","article-title":"Serum antinuclear antibodies associate with worse prognosis in AQP4-positive neuromyelitis optica spectrum disorder","volume":"11","author":"Fan","year":"2021","journal-title":"Brain Behav."},{"issue":"1","key":"10.1016\/j.msard.2026.107022_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75013-z","article-title":"Assessment of disability and disease burden in neuromyelitis optica spectrum disorders in the CIRCLES Cohort","volume":"14","author":"Gholizadeh","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2026.107022_bib0012","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13760-019-01176-6","article-title":"Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders","volume":"120","author":"Gkaniatsou","year":"2020","journal-title":"Acta Neurol. Belg."},{"issue":"2","key":"10.1016\/j.msard.2026.107022_bib0013","article-title":"Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder","volume":"10","author":"Hayes","year":"2024","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107022_bib0014","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of Neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.107022_bib0015","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J. Neurol."},{"issue":"14","key":"10.1016\/j.msard.2026.107022_bib0016","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/1352458516687403","article-title":"Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders","volume":"23","author":"Kim","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107022_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2018.11.022","article-title":"Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder","volume":"130","author":"Kim","year":"2019","journal-title":"Neurochem. Int."},{"issue":"2","key":"10.1016\/j.msard.2026.107022_bib0018","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3988\/jcn.2024.0485","article-title":"Evaluating Rituximab failure rates in Neuromyelitis optica spectrum disorder: a nationwide real-world study from South Korea","volume":"21","author":"Kim","year":"2025","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2026.107022_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1575613","article-title":"Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)","volume":"16","author":"Kretschmer","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2026.107022_bib0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107022_bib0021","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12964-019-0471-y","article-title":"The regulatory roles of neutrophils in adaptive immunity","volume":"17","author":"Li","year":"2019","journal-title":"Cell Commun. Signal."},{"issue":"10","key":"10.1016\/j.msard.2026.107022_bib0022","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s10072-017-3068-5","article-title":"Neutrophil to lymphocyte ratio may be a helpful marker to evaluate disease activity in NMOSD","volume":"38","author":"Lin","year":"2017","journal-title":"Neurol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2026.107022_bib0023","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/ene.12714","article-title":"Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica","volume":"23","author":"Masuda","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107022_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104517","article-title":"Clinical characteristics of late-onset neuromyelitis optica spectrum disorder","volume":"70","author":"Min","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2026.107022_bib0025","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107022_bib0026","unstructured":"NLEM, 2022. National list of essential medicines. Available from: https:\/\/ndi.fda.moph.go.th\/uploads\/file_news\/20220808893215585.PDF. (Accessed December 9 2025)."},{"issue":"4","key":"10.1016\/j.msard.2026.107022_bib0027","first-page":"311","article-title":"Clinical efficacy and safety of single cycle rituximab as induction therapy for aggressive neuromyelitis optica spectrum disorder in a resource limited center: a preliminary study","volume":"7","author":"Ong","year":"2020","journal-title":"Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2026.107022_bib0028","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1038\/s41598-024-53838-y","article-title":"Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"14","author":"Ongphichetmetha","year":"2024","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.msard.2026.107022_bib0029","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107022_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120039","article-title":"Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population","volume":"431","author":"Papathanasiou","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2026.107022_bib0031","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of Neuromyelitis optica","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2026.107022_bib0032","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jnnp-2022-330714","article-title":"Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum","volume":"94","author":"Park","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2026.107022_bib0033","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/neu.2016.49","article-title":"Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica","volume":"29","author":"Pereira","year":"2017","journal-title":"Acta Neuropsychiatr."},{"issue":"1","key":"10.1016\/j.msard.2026.107022_bib0034","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch. Neurol."},{"issue":"15","key":"10.1016\/j.msard.2026.107022_bib0035","doi-asserted-by":"crossref","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","article-title":"Evaluation of efficacy and tolerability of first-line therapies in NMOSD","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107022_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105452","article-title":"Predictors of azathioprine and mycophenolate mofetil response in patients with neuromyelitis optica spectrum disorder: a cohort study","volume":"83","author":"San Martin","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107022_bib0037","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3988\/jcn.2021.17.4.599","article-title":"Relapse after cessation of immunosuppressants in seropositive neuromyelitis optica spectrum disorder with long-term remission","volume":"17","author":"Seok","year":"2021","journal-title":"J. Clin. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107022_bib0038","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1212\/NXI.0000000000000607","article-title":"Late-onset neuromyelitis optica spectrum disorder","volume":"6","author":"Sepulveda","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"13","key":"10.1016\/j.msard.2026.107022_bib0039","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/1352458517731914","article-title":"Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies","volume":"24","author":"Sep\u00falveda","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107022_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106160","article-title":"Early rituximab versus escalating therapy in neuromyelitis optica: a cost and quality of life analysis","volume":"92","author":"Silva","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107022_bib0041","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107022_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103730","article-title":"Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration","volume":"60","author":"Tahara","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107022_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103907","article-title":"A quarter-century report on neuromyelitis optica spectrum disorder in Thailand: a single-center tertiary care cohort","volume":"63","author":"Tisavipat","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.107022_bib0044","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00415-025-13425-1","article-title":"Predictors of relapse and disability in NMOSD, MOGAD, and double-seronegative demyelinating syndromes: an international multicenter retrospective cohort study","volume":"272","author":"Tun\u00e7","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107022_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106580","article-title":"Real-world data and patient perspectives on the impact of multiple sclerosis, neuromyelitis optica spectrum disorder, and related disorders on employment","volume":"101","author":"Uawithya","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107022_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578151","article-title":"Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder","volume":"382","author":"Wang","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107022_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102843","article-title":"Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis","volume":"50","author":"Wang","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107022_bib0048","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2026.107022_bib0049","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2026.107022_bib0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3390\/jcm7120511","article-title":"The emerging role of neutrophil granulocytes in multiple sclerosis","volume":"7","author":"Woodberry","year":"2018","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.msard.2026.107022_bib0051","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12883-021-02432-0","article-title":"Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum disorder (NMOSD): a retrospective cohort study","volume":"21","author":"Xie","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2026.107022_bib0052","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fneur.2022.859276","article-title":"Relatively early and late-onset Neuromyelitis optica spectrum disorder in Central China: clinical characteristics and prognostic features","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2026.107022_bib0053","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107022_bib0054","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s10072-021-05609-0","article-title":"Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors","volume":"43","author":"Zhang","year":"2022","journal-title":"Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2026.107022_bib0055","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/00207454.2016.1254630","article-title":"Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders","volume":"127","author":"Zhang","year":"2017","journal-title":"Int. J. Neurosci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:54:17Z","timestamp":1780415657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":55,"alternative-id":["S2211034826000581"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107022","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline severe disability as a predictor of treatment escalation to rituximab in AQP4-IgG\u2013positive NMOSD patients: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107022"}}